Synonyms: CDP-7657 | CDP7657 | DZP
Compound class:
Antibody
Comment: Dapirolizumab pegol (CDP7657) is a pegylated monovalent Fab' immunomodulator that targets CD40 ligand [1]. It was developed by UCB Pharma. Removal of the Fc domain prevented the increased risk of thrombotic events observed with an intact mAb.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
9869 | dapirolizumab pegol |
Synonyms ![]() |
CDP-7657 | CDP7657 | DZP |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 481 |
Other databases | |
CAS Registry No. | 1416147-64-2 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL2109478 |
GtoPdb PubChem SID | 434122183 |
Search PubMed clinical trials | dapirolizumab pegol |
Search PubMed titles | dapirolizumab pegol |
Search PubMed titles/abstracts | dapirolizumab pegol |